May 12, 2026 — Tonix Pharmaceuticals (NASDAQ: TNXP) reported first-quarter 2026 financial results while highlighting continued commercial momentum for TONMYA, its recently launched fibromyalgia treatment, and advancement across its clinical pipeline. The company said TONMYA, the first new fibromyalgia medicine in 15 years, has shown growth in prescriptions, prescribers, refills and patient access since its November 2025 launch, with a recently announced managed care agreement expanding potential coverage to approximately 35 million U.
May 12, 2026 — Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms.
May 12, 2026 — This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.
May 12, 2026 — Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial highlights Oncotelic’s proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain, positioning the company within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications and other CNS-related conditions.
May 12, 2026 — In a blog post by Daniel Azoulai, Qdrant highlighted how Sapu, an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers, uses Qdrant Cloud infrastructure to power an AI research platform capable of indexing and querying all 28 million PubMed abstracts in a single searchable collection, helping accelerate biomedical discovery workflows. According to the post, Sapu’s AI platform evolved from an early prototype into a production-scale system supporting scientific literature review, standard operating procedure retrieval and AI-assisted research authorship.
May 12, 2026 — This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.
May 12, 2026 — This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.
May 12, 2026 — Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement.
May 11, 2026 — A new report from congressional researchers is shedding light on what the Trump administration’s move to reclassify cannabis could mean for the industry, while also outlining the limits of the policy shift under federal law. As the ramifications of the recent decision to reclassify some marijuana products continue to become clearer, marijuana companies like Tilray Brands Inc.
May 11, 2026 — Pershing Square USA (NYSE: PSUS) and Pershing Square Inc. (NYSE: PS) announced the closing of their combined initial public offerings and previously announced combined private placement, generating gross proceeds of $5 billion for PSUS before deducting sales loads, placement fees and offering expenses.
May 11, 2026 — Delta Gold Technologies (Aquis: DGQ /OTC:DGQTF) is featured in the debut episode of The Innovation Report Series, a new documentary initiative exploring technologies, industries and companies shaping the future global economy. The first episode, The Quantum Revolution, examines the advancing commercial potential of quantum technologies and their potential impact across industries, while the broader series explores the intersection of innovation, capital markets and industrial transformation.
May 11, 2026 — This article has been disseminated on behalf of Oregen Energy Corp. and may include paid advertising.
May 11, 2026 — This article has been disseminated on behalf of Oregen Energy Corp. and may include paid advertising.
May 11, 2026 — This article has been disseminated on behalf of Oregen Energy Corp. and may include paid advertising.
May 11, 2026 — Twin Vee PowerCats (NASDAQ: VEEE)reported first-quarter 2026 revenue growth of approximately 10% year over year and 31% sequentially, marking its fourth consecutive quarter of year-over-year revenue gains, as the company continued expanding its product lineup with the relaunch of Bahama Boat Works. Twin Vee posted a net loss of $2.
May 11, 2026 — Datavault AI (NASDAQ: DVLT) highlighted the strategic positioning of its distributed edge computing network ahead of this week’s anticipated U. S.
May 11, 2026 — Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement.
May 11, 2026 — This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising.
May 11, 2026 — HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection within an established approximately $2 billion patch-based monitoring market.
May 11, 2026 — The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital.
